JP2022551495A5 - - Google Patents

Info

Publication number
JP2022551495A5
JP2022551495A5 JP2022521432A JP2022521432A JP2022551495A5 JP 2022551495 A5 JP2022551495 A5 JP 2022551495A5 JP 2022521432 A JP2022521432 A JP 2022521432A JP 2022521432 A JP2022521432 A JP 2022521432A JP 2022551495 A5 JP2022551495 A5 JP 2022551495A5
Authority
JP
Japan
Prior art keywords
cancer
melanoma
composition according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551495A (ja
JP7631329B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/055121 external-priority patent/WO2021072300A1/en
Publication of JP2022551495A publication Critical patent/JP2022551495A/ja
Publication of JP2022551495A5 publication Critical patent/JP2022551495A5/ja
Application granted granted Critical
Publication of JP7631329B2 publication Critical patent/JP7631329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521432A 2019-10-10 2020-10-09 リン脂質-フラバグリン抱合体及び標的化されたがん治療のためのリン脂質-フラバグリン抱合体の使用方法 Active JP7631329B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913571P 2019-10-10 2019-10-10
US62/913,571 2019-10-10
PCT/US2020/055121 WO2021072300A1 (en) 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (3)

Publication Number Publication Date
JP2022551495A JP2022551495A (ja) 2022-12-09
JP2022551495A5 true JP2022551495A5 (cg-RX-API-DMAC7.html) 2023-10-16
JP7631329B2 JP7631329B2 (ja) 2025-02-18

Family

ID=75436788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521432A Active JP7631329B2 (ja) 2019-10-10 2020-10-09 リン脂質-フラバグリン抱合体及び標的化されたがん治療のためのリン脂質-フラバグリン抱合体の使用方法

Country Status (11)

Country Link
US (1) US12496346B2 (cg-RX-API-DMAC7.html)
EP (1) EP4041718A4 (cg-RX-API-DMAC7.html)
JP (1) JP7631329B2 (cg-RX-API-DMAC7.html)
KR (1) KR102973364B1 (cg-RX-API-DMAC7.html)
CN (1) CN114761389B (cg-RX-API-DMAC7.html)
AU (1) AU2020361679B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022006739B1 (cg-RX-API-DMAC7.html)
CA (1) CA3154192A1 (cg-RX-API-DMAC7.html)
IL (1) IL291979B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004341A (cg-RX-API-DMAC7.html)
WO (1) WO2021072300A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200017A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
KR102973364B1 (ko) 2019-10-10 2026-06-04 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
WO2025073824A1 (en) * 2023-10-03 2025-04-10 Aarhus Universitet Phospholipid conjugates and their uses

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE4132344A1 (de) 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE4408011C1 (de) 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
WO1998024480A1 (en) 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
WO2006014589A2 (en) 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DE602005015687D1 (de) 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
US7632644B2 (en) 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
MX2007007497A (es) 2004-12-20 2008-01-11 Cellectar Llc Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.
US20070167408A1 (en) 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
US8022235B2 (en) 2007-06-01 2011-09-20 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
CN101878024B (zh) 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
US20100286510A1 (en) 2009-05-11 2010-11-11 Pinchuk Anatoly Use of fluorescent phospholipid ether compounds in biopsies
WO2010132428A1 (en) 2009-05-11 2010-11-18 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US7811548B1 (en) 2009-05-11 2010-10-12 Cellectar, Inc. Fluorescent phospholipid ether compounds and compositions
DK3708192T3 (da) * 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
WO2011031919A2 (en) 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2014106826A2 (en) 2013-01-07 2014-07-10 Piramal Enterprises Limited Anthracycline analogue and uses thereof
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
SG11201701565PA (en) 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
KR102934754B1 (ko) 2015-11-25 2026-03-04 이펙터 테라퓨틱스, 인크. Eif4a-억제 화합물 및 이에 관련된 방법
CN109310702A (zh) 2016-05-20 2019-02-05 芝加哥大学 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
JP7043425B2 (ja) * 2016-06-06 2022-03-29 ジェネンテック, インコーポレイテッド シルベストロール抗体-薬物コンジュゲート及び使用方法
CN109791152B (zh) 2016-06-14 2023-03-03 塞勒科塔生物科学公司 用于鉴定和分离循环肿瘤细胞的磷脂醚类似物
KR20200015540A (ko) 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드
CA3086454A1 (en) 2017-09-26 2019-04-04 National University Corporation Chiba University Radioactive drug
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
WO2019200017A1 (en) 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
CA3097101A1 (en) 2018-04-16 2019-10-24 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
KR102973364B1 (ko) 2019-10-10 2026-06-04 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법

Similar Documents

Publication Publication Date Title
JP2022088662A5 (cg-RX-API-DMAC7.html)
Vasefifar et al. Nanog, as a key cancer stem cell marker in tumor progression
Treps et al. Vasculogenic mimicry, a complex and devious process favoring tumorigenesis–Interest in making it a therapeutic target
JP2022548057A5 (cg-RX-API-DMAC7.html)
JP2019519467A5 (cg-RX-API-DMAC7.html)
Xu et al. Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway
JP2023500483A5 (cg-RX-API-DMAC7.html)
JP2024506612A5 (cg-RX-API-DMAC7.html)
CN110545820A (zh) 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
JP2018507249A5 (cg-RX-API-DMAC7.html)
JP2016538344A5 (cg-RX-API-DMAC7.html)
Petricevic et al. Neoadjuvant immunotherapy in gastrointestinal cancers–the new standard of care?
IL291979B1 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
JP2017530171A5 (cg-RX-API-DMAC7.html)
JP2013523680A5 (cg-RX-API-DMAC7.html)
JP2022501441A5 (cg-RX-API-DMAC7.html)
Hu et al. Thiosemicarbazone-based selective proliferation inactivators inhibit gastric cancer cell growth, invasion, and migration
Ke-Chun et al. The role of SPDEF in cancer: promoter or suppressor.
CN110494131A (zh) 精胺及其衍生物在制备抗肿瘤药物中的应用
JP2019511525A5 (cg-RX-API-DMAC7.html)
RU2015156221A (ru) Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
Liang et al. The clinicopathological and prognostic value of Nanog in human gastrointestinal luminal cancer: A meta-analysis
NO20045249L (no) Epotilonderivat for behandling av hepatom og andre kreftsykdommer
RU2025120853A (ru) Применение катионной липосомы паклитаксела в лечении опухолей
JP2022547885A5 (cg-RX-API-DMAC7.html)